Jiangsu Kanion Pharmaceutical600557.SHValuation Analysis

As of Oct 19, 2026, Jiangsu Kanion Pharmaceutical (600557.SH) trades at a P/E of 22.60x, P/B of 1.41x, P/S of 2.10x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 55th percentile over the trailing 10Y window (vs. 52nd percentile over 3Y); P/B sits at the 6th percentile over the trailing 10Y window (vs. 12th percentile over 3Y); P/S sits at the 46th percentile over the trailing 10Y window (vs. 44th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 27th percentile within its industry and the 30th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B percentiles diverge here, differing by 49.3 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Jiangsu Kanion Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.